Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on Pharmacokinetics of EVG/COBI/FTC/TAF FDC in Healthy Japanese Male Volunteers
jRCT1080223252Phase 1
- Sponsor
- Torii Pharmaceutical
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by Torii Pharmaceutical. Primary endpoint: Primary pharmacokinetic parameters of EVG/COBI/FTC/TAF under fed vs fasting conditions.
02
Drugs
elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on jRCT1080223252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080223252.